HMGB1 and breast carcinoma: More importantly, in vivo experiments showed that 22 of 41 patients treated with the drug combination who exhibited pathologically complete remission or partial remission responders were accompanied by a significant increase in HMGB1 levels, while the remaining 19 patients did not show any significant changes in breast cancer pathological features with plasma HMGB1 levels 123.